ClinicalTrials.gg

Program

seladelpar

Also written as “Seladelpar”, “MBX-8025” and “Seladelpar 10 mg”.

Its studies are mostly in Liver Cirrhosis, Biliary · Cholangitis, Sclerosing · Non-alcoholic Fatty Liver Disease · Homozygous Familial Hypercholesterolemia · Hyperlipidemias, led by Gilead Sciences.

Furthest: phase 3, since Sep 26, 201714 company-led studies, 3 open or runningNext primary completion: Nov 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences143 open or runningphase 3since Sep 26, 2017Jun 17, 2008Nov 2028phase 3 · NCT03301506

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2008First study: phase 2 study in HyperlipidemiasFirst studyNCT00701883 · 183 enrolled · United States
  2. May 22, 2015Phase 2 study in Homozygous Familial HypercholesterolemiaNCT02472535 · 13 enrolled · Canada, France, Netherlands and more
  3. Nov 13, 2015Phase 2 study in Liver Cirrhosis, BiliaryNCT02609048 · 41 enrolled · United States, Canada, Germany and more
  4. Nov 2, 2016Phase 2 study in Liver Cirrhosis, BiliaryNCT02955602 · 119 enrolled · United States, Canada, Germany and more
  5. Sep 26, 2017Phase 3 study in Liver Cirrhosis, BiliaryNCT03301506 · 340 enrolled · United States, Argentina, Australia and more
  6. Nov 16, 2017Phase 1 study in Hepatic ImpairmentNCT03369002 · 32 enrolled · United States
  7. May 9, 2018Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03551522 · 181 enrolled · United States
  8. Jul 18, 2018Phase 3 study in Liver Cirrhosis, BiliaryNCT03602560 · 265 enrolled · United States, Argentina, Australia and more
  9. Jun 20, 2019Phase 2 study in Cholangitis, SclerosingNCT04024813 · 1 enrolled · United States, Canada, Poland
  10. Nov 4, 2020Phase 3 study in Liver Cirrhosis, BiliaryNCT04620733 · 193 enrolled · United States, Argentina, Australia and more
  11. Jun 14, 2021Phase 1 study in Liver Cirrhosis, BiliaryNCT04950764 · 24 enrolled · United States, South Korea, Spain and more
  12. Sep 18, 20232 phase 3 studies in Liver Cirrhosis, BiliaryNCT06051617, NCT06060665
  13. Sep 21, 2026Phase 2 study in Liver Cirrhosis, BiliaryNCT07841977 · 132 planned · United States
  14. Oct 27, 2026Primary completion moved from 2028-06 to 2028-12Date moved laterphase 2 · +6 months · NCT07841977

Ahead

  1. Nov 2028Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT03301506
  2. Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryNCT07841977
  3. Aug 2030Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06051617

TargetBeta

PPARA →PPARD →read by rule
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-delta (PPARd), with bile acids reducing activity”NCIt, by rule
“Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor delta agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07841977Liver Cirrhosis, Biliary · United States2RecruitingDec 2028132
NCT06060665Liver Cirrhosis, Biliary · United States, Canada3CompletedMay 6, 202696
NCT06051617Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3RecruitingAug 2030402
NCT04950764Liver Cirrhosis, Biliary · United States, South Korea, Spain and more1CompletedFeb 24, 202524
NCT04620733Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3CompletedAug 11, 2023193
NCT04024813Cholangitis, Sclerosing · United States, Canada, Poland2TerminatedJan 9, 20201
NCT03602560Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3CompletedFeb 16, 2020265
NCT03551522Non-alcoholic Fatty Liver Disease · United States2TerminatedMay 8, 2019181
NCT03369002Hepatic Impairment · United States1CompletedMay 15, 201832
NCT03301506Liver Cirrhosis, Biliary · United States, Argentina, Australia and more3Active, not recruitingNov 2028340
NCT02955602Liver Cirrhosis, Biliary · United States, Canada, Germany and more2CompletedSep 7, 2018119
NCT02609048Liver Cirrhosis, Biliary · United States, Canada, Germany and more2TerminatedJul 1, 201641
NCT02472535Homozygous Familial Hypercholesterolemia · Canada, France, Netherlands and more2CompletedFeb 201613
NCT00701883Hyperlipidemias · United States2CompletedAug 2008183

How it is read

Names in the registry

  • “Seladelpar”, 5 entries
  • “MBX-8025”, 4 entries
  • “Seladelpar 10 mg”, 2 entries
  • “Seladelpar 5 mg Capsule”, 1 entry
  • “Seladelpar 10 mg Capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.